Enhancement of radiation response of prostatic carcinoma by lonidamine

Anticancer Research

Volumn 16, Issue 6 B, 1996, Pages 3665-3672

  Dudak, Scott D ^a   Lopez, Armando ^b   Block, Norman L ^a   Lokeshwar, Bal L ^a,c  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b Lake City VA Hospital   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Adjuvant trherapy; Ionidamine; Prostate cancer; Radiation

Indexed keywords

ANTINEOPLASTIC AGENT; LONIDAMINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL CULTURE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY; HUMAN; HUMAN CELL; MALE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CARCINOMA; RADIATION DOSE FRACTIONATION; RADIATION RESPONSE; RAT;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL CYCLE; COMBINED MODALITY THERAPY; DNA REPAIR; HUMANS; INDAZOLES; MALE; PROSTATIC NEOPLASMS; RADIATION-SENSITIZING AGENTS; RATS; TUMOR CELLS, CULTURED;

EID: 0030514287     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Parker SL, Tong T, Bolden S, Wingo PA. Cancer Statistics, 1996. CA: Cancer J Clin 65: 5-27, 1996.
2. Hanks GE, Martz KL, Diamond JJ: The effect of dose on local control of prostate cancer. Int J Rad Oncol Biol Phys 15: 1299-1305, 1988.
3. Zietman AL, Shipley WU, Willett CG: Residual disease after radical surgery or radiation therapy for prostate cancer. Cancer 71: 959-969, 1993.
4. Eklov S, Essand M, Carlsson J, Wilsson S: Radiation sensitization by estramustine: studies on cultured human prostatic cancer cells. Prostate 21: 287-295, 1992.
5. Lokeshwar BL, Ferrell SM, Block NL: Radiation sensitization of prostatic carcinoma by taxol: Potential for therapeutic application in advanced malignancy. Anticancer Res 15: 93-98, 1995.
6. Kim JH, Alfieri AA, Kim SH, Young CW: Potentiation of radiation effects on two murine tumors by Ionidamine. Cancer Res 46: 1120-1123, 1986
7. Silvestrini B: Lonidamine: An overview. Semin Oncol 18: 2-6, 1991.
8. Floridi A, Paggi MG, Marcante ML, Silvestrini B, Caputo A and DcMartino C: Lonidamine, a selective inhibitor of aerobic glycolysis of murine tumor cells. J Nat Cancer Ins 66: 497-499, 1981.
9. Floridi A, Paggi MG, D'Atri S, DeMartino C, Mercante ML, Silvestrini B, Caputo A: Effect of Ionidamine on the energy metabolism of Ehrlich ascites tumor cells. Cancer Res 41: 4661-4666, 1981.
10. Santini MT, Cametti C, Indovina PL, Malorni W, Benassi M, Gentile FP, Castiglione S and Floridi A: Effects of Ionidamine on the membrane electrical properties of Ehrlich ascites tumor cells. FEBS 291: 166-172, 1991.
11. Malorni W, Meschini S, Matarrese P, Arancia G: The cytoskeleton as a subcellular target of the antineoplastic drug Ionidamine. Anticancer Res 12: 2037-2046, 1992.
12. Hahn GM, van Kersen I, Silvestrini B: Inhibition of the recovery from potentially lethal damage by LND. Br J Cancer 50: 657-660, 1984.
13. Raaphorst GP, Feeley MM, Danjoux CE, Martin L, Maroun J, DeSanctis AJ. The effect of LND (LND) on radiation and thermal responses of human and rodent cell lines. Int J Rad Onc Biol Phys 20: 509-515, 1991.
14. Bloch WE, Lokeshwar BL, Ferrell SM and Block NL: Enhancement of hyperthermic toxicity by LND in the Dunning R3327G rat prostatic adenocarcinoma. Prostate 24: 131-138, 1994.
15. Teicher BA, Holden SA, Herman TS, Frei E. Modulation of alkylating agents by Ionidamine in vivo. Sem Oncology 18: 7-10, 1991.
16. Cionini L: Radiotherapy plus LND in non-small cell lung cancer: Sem Onc 18: 49-52, 1991.
17. Scarantino CW, McCunniff AJ, Evans G, Young CW, Paggiarino DA: Prospective randomized comparison of radiation therapy plus LND versus radiation therapy plus placebo as initial treatment of clinically localized but nonresectable nonsmall cell lung cancer. Int J Rad Onc 29: 999-1004, 1994.
18. Scarantino CW, Newton RE, Puggiarino DA, Degregario M: Lonidamine in head and neck cancer. Sem Onc 18: 28-32, 1991.
19. Calabresi F, Di Lauro L, Marolla P, Curcio CG, Paoletti G, Calabro A, Giannarelli D, Ballatore P, Foggi CM, Di Palma M, Stolfi R, Cortesi E: Fluorouracil, doxorubicin, and cyclophosphamide versus fluorouracil, doxorubicin, and cyclophosphamide plus LND for the treatment of advanced breast cancer: A multicentric randomized clinical study. Sem Onc 18: 66-72, 1991.
20. Rosso R, Gradin G, Pronzato P, Camoriano A, Merlini L, Naso C, Rosso M, Barone C, Nascimben O, Ianniello G, Sturba F, Contu A, Buldini E, Gianness PG, Conte PF. The role of Ionidamine in the treatment of breast cancer patients. Annals N Y Acad Sci 698: 349-356, 1993.
21. Possinger K, Wagner H, Kovacs S, Flath B, Classen S, Wilmanns W: Lonidamine in high-risk breast cancer patients. Sem Onc 18: 58-61, 1991.
22. Stewart DJ, Aitken SE, Irvine AK, Moors DE, Fulter NG: Phase II study of Ionidamine in metastatic prostatic carcinoma. Invest New Drugs 9: 343-344, 1991.
23. Romijn JC, Verkoelen CF, Schroeder FH: Application of the MTT assay to human prostate cancer cell lines in vitro: Establishment of test conditions and assessment of hormone-stimulated growth and drug-induced cytostatic and cytotoxic effects. Prostate 12: 99-110, 1988.
24. Fertil B, Malaise EP: Intrinsic radiosensitivity of human cell lines is correlated with radioresponsiveness of human tumors: Analysis of 101 published survival curves. Int Natl J Rad Oncol Biol Phy 11: 1699-1707, 1985.
25. Hall EJ: Chemotherapeutic agents from the perspective of the radiation biologist. In: Radiobiology for the radiologist, Ed. 3, pp332-356. J B Lippincott, Philadelphia, 1988.
26. Sinclair WK, Morton RA: X-ray sensitivity during the cell generation cycle of cultured chinese hamster cells. Rad Res 29: 450-474, 1966.
27. Leith JT, Quaranto L, Padfidd G, Michelson S, Hercbergs A: Radiobiological studies of PC-3 and DU 145 human prostate cancer cells: x-ray sensitivity in vitro and hypoxic tractions off xenografted tumors in vivo. Int J Rad Oncol Biol Phys 25: 283-287, 1993.
28. Thorndyke C, Meeker BE, Thomas G, Lakey WH, McPhee MS, Chapman JD: The radiation sensitivities of R3327-H and R3327-AT rat prostate adenocarcinomas. J Urol. 134: 191-198, 1985.
29. Delia Cuna GR, Pedrazzoli P: Toxicity and clinical tolerance of Ionidamine. Sem Onc 18: 18-22, 1991.